

**UNITED GENE HIGH-TECH GROUP LTD:  
CITIC SECURITIES BROKERAGE (HONGKONG) LTD.  
GOES ALL OUT TO NOBBLE MR CAI CHONG ZHEN**

The former Chairman of Far East Pharmaceutical Technology Company Ltd () (Code: 399, Main Board, The Stock Exchange of Hongkong Ltd) appears to be suffering from a small financial problem.

CITIC Securities Brokerage (Hongkong) Ltd ([]) has just fired off a Writ of Summons in the High Court of the Hongkong Special Administrative Region (HKSAR) of the People's Republic of China (PRC), naming a British Virgin Islands company, Great Wall Investment Group Ltd, in which Mr Cai Chong Zhen () is said to own an equitable interest, as the Defendant.

CITIC Securities Brokerage (Hongkong) Ltd is claiming about \$HK27.56 million from the Defendant.

Mr Cai Chong Zhen was the Chairman of Far East Pharmaceutical Technology Company Ltd until September 1, 2004, and he had, at one time, about 40.60 percent of the Issued and Fully Paid-Up Share Capital of this publicly listed company.

Today, Far East Pharmaceutical Technology Company Ltd is known as United Gene High-Tech Group Ltd (), its name, having been changed on March 3, 2009.

The case for the Plaintiff in respect of High Court Action, Number 2003, is contained in the Statement of Claim, attached to the Writ of Summons.

It alleges that Great Wall Investment Group Ltd

*'(2) at the material times held a 40.60% interest in Far East Pharmaceutical Technology Company Limited ("**FEPTCL**"). The Defendant holds this interest on trust for "The Great Wall Unit Trust", in turn a unit trust of which all the units in issue are owned by Trident Corporate Services (B.V.I.) Limited in its capacity as the trustee of "The C & C Trust", a discretionary family trust of which the objects include Cai Chong Zhen ("**Cai**") and his spouse and the family member of Chen Ching Ken ("**Chen**");*

*'(3) at the material times a client of the Plaintiff from about November 2003 to April 2008.'*

Messrs Cai Chong Zhen and Chen Ching Ken () were Executive Directors of Far East Pharmaceutical Technology Company Ltd.

It is alleged, at Paragraph 7 of the Statement of Claim, that the Plaintiff had the following clients, all of whom, since about March 2003, had acquired substantial shares in the Issued and Fully Paid-Up Share Capital of Far East Pharmaceutical Technology Company Ltd on margin.

Those clients are named as being:

- '(1) Li Jia ("**Li**");*
- (2) Sun Ya Cheng ("**Sun**");*
- (3) Bao Ping ("**Bao**") and Wang Yuan ("**Y. Wang**");*

- (4) Wang Cui Xia (“**C. X. Wang**”);
- (5) Wang Rui Yun (“**R. Y. Wang**”);
- (6) Cheng Yan (“**Cheng**”);
- (7) Improve Future Finance Limited (“**Improve Future**”); and
- (8) Info Dragon Investments Limited (“**Info Dragon**”).’

Paragraph ... [CLICK TO ORDER FULL ARTICLE](#)

*While **TARGET** makes every attempt to ensure accuracy of all data published, **TARGET** cannot be held responsible for any errors and/or omissions.*

*If readers feel that they would like to voice their opinions about that which they have read in **TARGET**, please feel free to e-mail your views to [editor@targetnewspapers.com](mailto:editor@targetnewspapers.com). **TARGET** does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.*